3. Patent Term Extension in India

Section 53 of the Indian Patents Act, 1970, generally provides a patent term of 20 years from the relevant filing date. India does not have a general patent-term restoration mechanism equivalent to the US system that extends a patent because pharmaceutical or biologic regulatory approval took several years.

IndiaCode

+1

This distinction is important for biologics because their development may require lengthy laboratory research, clinical trials, manufacturing validation and regulatory review. In India, the ordinary patent term does not automatically increase to compensate for these delays.

4. Important Case Laws

A. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990)

The US Supreme Court interpreted provisions of the Hatch–Waxman Act concerning patent-term extension and the categories of patents eligible for restoration following regulatory review. The Court examined how the statutory scheme applied to patents involving medical devices.

Legal principle: Patent-term extension depends on the precise statutory eligibility requirements; it is not an automatic consequence of regulatory delay. Although this case was not about biologics, its interpretation of the extension framework is relevant to regulated medical products.

U.S. Code

+1

B. Merck & Co., Inc. v. Hi-Tech Pharmacal Co., 482 F.3d 1317 (Fed. Cir. 2007)

The US Court of Appeals for the Federal Circuit considered the interaction between patent-term extension under 35 U.S.C. § 156 and a terminal disclaimer affecting patent duration.

The Court held that a patent could receive the statutory extension despite the terminal disclaimer, provided the statutory requirements were satisfied.

Legal principle: Patent-term extension must be analysed according to the governing legislation and its eligibility conditions, rather than assuming that every restriction on ordinary patent duration automatically prevents restoration.

USPTO

+1

C. Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010)

The Federal Circuit considered patent-term adjustment resulting from delays by the US Patent and Trademark Office. It ruled on how statutory periods of delay should be calculated.

Legal principle: This case concerns administrative delay during patent prosecution, not biologic regulatory-review extension. It illustrates the distinction between extending a patent because of patent-office delay and restoring part of its term because of regulatory approval delays.

cafc.uscourts.gov

+1

5. Policy Considerations

Patent-term extension can help compensate innovators for time lost during mandatory regulatory review, encouraging investment in complex biologic medicines. However, prolonged exclusivity can delay biosimilar competition, maintain high prices and restrict patient access. Any extension should therefore be limited to qualifying patents, supported by evidence and confined to the statutory scope.

Conclusion

Patent-term extension for biologics reflects the tension between rewarding pharmaceutical innovation and ensuring timely biosimilar competition. In India, Section 53 of the Patents Act, 1970, generally fixes the patent term at 20 years without a general regulatory-delay extension. By contrast, the United States provides a limited restoration mechanism under 35 U.S.C. § 156 for qualifying products. The cited cases demonstrate that extension depends on statutory eligibility, calculation rules and the precise rights claimed.